PHARMACYTE BIOTECH INC (PMCB) Stock News

NASDAQ:PMCB - Nasdaq - US71715X2036 - Common Stock - Currency: USD

0.8999 +0.01 (+1.25%)

After market: 0.8998 0 (-0.01%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PMCB Latest News, Press Relases and Analysis

All

Press Releases

3 months ago - By: Benzinga - Mentions: LUCY WORX SNTI UPC ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

a year ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

a year ago - By: InvestorPlace

PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024

a year ago - By: BusinessInsider

News Image

PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024

2 years ago - By: BusinessInsider

News Image

PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024

2 years ago - By: InvestorPlace

PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024

2 years ago - By: Benzinga - Mentions: AMPE SBFM PHAR CDNA ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

2 years ago - By: PharmaCyte Biotech, Inc. - Mentions: FEMY

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.

2 years ago - By: Femasys Inc. - Mentions: FEMY

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

2 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

3 years ago - By: Iroquois Capital Management, LLC

News Image

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS

2 years ago - By: Seeking Alpha

PharmaCyte stock completes tender offer to purchase shares

3 years ago - By: Iroquois Capital Management, LLC

News Image

IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS

2 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Announces Final Results of Tender Offer

2 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

3 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

3 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

3 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

3 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation

3 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

3 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

3 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

3 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

3 years ago - By: Iroquois Capital Management, LLC

News Image

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING

3 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

3 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

3 years ago - By: PharmaCyte Biotech

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

3 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

3 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

3 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

3 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

3 years ago - By: PharmaCyte Biotech, Inc.

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial